




RealRate

PHARMACEUTICAL 2018

Checkpoint Therapeutics Inc
Rank 214 of 332



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Checkpoint Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Checkpoint Therapeutics Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 58% points. The greatest weakness of Checkpoint Therapeutics Inc is the variable Research and Development, reducing the Economic Capital Ratio by 66% points.

The company's Economic Capital Ratio, given in the ranking table, is 208%, being 44% points below the market average of 252%.

Input Variable	Value in 1000 USD
Assets, Current	21,413
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	6,372
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	98
Other Revenues	1,725
Property and Equipment	0
Research and Development	19,081
Selling, General and Administrative Expense	5,419

Output Variable	Value in 1000 USD
Assets	21,413
Liabilities	6,372
Expenses	24,500
Revenues	1,725
Stockholders Equity	15,041
Net Income	-22,677
Comprehensive Net Income	-22,677
BaseVar	27,054
ECR before Limited Liability	73%
Economic Capital Ratio	208%